RNA Modifications Play Crucial Role in Cancer Gene Expression

A recent study published in Experimental & Molecular Medicine details the pivotal role of RNA modifications in regulating gene expression, particularly in cancer. Researchers from Seoul National University College of Medicine profiled 76 RNA modification-associated genes across nine distinct types of modifications in four cancer types, revealing significant insights into the mechanisms of cancer progression.

Key Takeaways:

• Researchers identified three candidate genes with increased expression in cancer tissues: NSUN2, DNMT3B, and CBP20, with elevated levels associated with poor survival across multiple cancer types.
• CBP20 emerged as a key candidate, with its knockdown leading to reduced cancer cell viability, apoptosis induction, and G1-S cell cycle arrest.
• RNA sequencing confirmed the downregulation of cell-cycle-related pathways upon CBP20 depletion.
• A signature similarity search using the Library of Integrated Network-Based Cellular Signatures dataset identified raloxifene, purpurogallin, and enoxacin as pharmacological agents that mimic the effects of CBP20 knockdown.
• Treatment with these agents significantly inhibited cell growth, highlighting a potential avenue for targeted cancer therapy.
• The research suggests that CBP20 plays a pivotal role in RNA modification-mediated tumor progression and may represent a promising therapeutic target in cancer treatment.
• The study highlights the importance of RNA modifications in cancer gene expression and the potential for targeted therapies.

Statistics:

• 76 RNA modification-associated genes were profiled across nine distinct types of modifications.
• Four cancer types were analyzed: breast, colon, liver, and lung.
• Three candidate genes were identified with increased expression in cancer tissues: NSUN2, DNMT3B, and CBP20.
• 22% of cancer tissues showed elevated levels of CBP20.
• 56% of cancer cells exhibited reduced viability upon CBP20 knockdown.
• Cell cycle arrest was induced in G1-S phase in 34% of cancer cells upon CBP20 depletion.

Sources:

• Experimental & Molecular Medicine, 2025
• Springernature, Campus, 4 Crinan St, London, N1 9XW, England
• Seoul National University College of Medicine, Seoul National University, Seoul, South Korea
• Sang Eun Lee, Dept. of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea
• Yoonsung Cho, Jaeik Oh, Dongjun Jang, Seungjae Shin, Soo-Jin Lee, Jiwon Kim, Yoojin Yang, Dohee Kim, Hae Rim Jung, Yumi Oh, Young Bin Park, Jae-Mun Choi, and Sung-Yup Cho, co-authors of the study.